Krikorian J G, Burke J S, Rosenberg S A, Kaplan H S
N Engl J Med. 1979 Mar 1;300(9):452-8. doi: 10.1056/NEJM197903013000902.
We studied the clinical and pathological features of six cases of non-Hodgkin's lymphoma (diffuse undifferentiated in four cases and diffuse histiocytic in two cases) occuring in patients treated for Hodgkin's disease. All six patients had received both radiation and chemotherapy. Abdominal or gastrointestinal involvement was present in five of the six cases. None of the patients had evidence of Hodgkin's disease when the diagnosis of non-Hodgkin's lymphoma was made. Five of the six patients were among a study group of 579 patients with Hodgkin's disease, prospectively followed since diagnosis. At 10 years the actuarial risk of development of non-Hodgkin's lymphoma in this study group is 4.4 per cent (1.2 to 15.0) (per cent probability with 95 per cent confidence limits) and is similar to that of developing acute leukemia: 2.0 per cent (0.3 to 12.9). Non-Hodgkin's lymphoma is a second tumor that may occur late in the course of patients treated for Hodgkin's disease--particularly in patients who have received both radiation therapy and chemotherapy. Like acute leukemia, non-Hodgkin's lymphoma may be another cancer that represents a substantial late risk of combined-modality therapy.
我们研究了6例在接受霍奇金病治疗的患者中发生的非霍奇金淋巴瘤(4例为弥漫性未分化型,2例为弥漫性组织细胞型)的临床和病理特征。所有6例患者均接受了放疗和化疗。6例中有5例出现腹部或胃肠道受累。在诊断非霍奇金淋巴瘤时,所有患者均无霍奇金病的证据。6例患者中有5例来自一个579例霍奇金病患者的研究组,自诊断后进行前瞻性随访。在该研究组中,10年时发生非霍奇金淋巴瘤的精算风险为4.4%(1.2%至15.0%)(95%置信区间的概率百分比),与发生急性白血病的风险相似:2.0%(0.3%至12.9%)。非霍奇金淋巴瘤是一种可能在霍奇金病患者病程后期发生的第二种肿瘤——尤其是那些接受了放疗和化疗的患者。与急性白血病一样,非霍奇金淋巴瘤可能是联合治疗带来显著晚期风险的另一种癌症。